Hepatitis B surface antigen-positive organ transplantation recipients: can lamivudine alter their fate?

about

Long-term effects of prophylactic and therapeutic lamivudine treatments in hepatitis B surface antigen-positive renal allograft recipients.

P2860

Q51877261-16EC61DB-F40E-4E0F-B271-B47E591FCA65

P2860

Hepatitis B surface antigen-positive organ transplantation recipients: can lamivudine alter their fate?

Item

http://www.wikidata.org/entity/Q43762350

description

2001 nî lūn-bûn

@nan

2001年の論文

@ja

2001年学术文章

@wuu

2001年学术文章

@zh-cn

2001年学术文章

@zh-hans

2001年学术文章

@zh-my

2001年学术文章

@zh-sg

2001年學術文章

@yue

2001年學術文章

@zh

2001年學術文章

@zh-hant

name

Hepatitis B surface antigen-po ...... n lamivudine alter their fate?

@en

Hepatitis B surface antigen-po ...... n lamivudine alter their fate?

@nl

type

Item

label

Hepatitis B surface antigen-po ...... n lamivudine alter their fate?

@en

Hepatitis B surface antigen-po ...... n lamivudine alter their fate?

@nl

prefLabel

Hepatitis B surface antigen-po ...... n lamivudine alter their fate?

@en

Hepatitis B surface antigen-po ...... n lamivudine alter their fate?

@nl

P1476

Hepatitis B surface antigen-po ...... n lamivudine alter their fate?

@en

P2093

Leung N

http://www.w3.org/2001/XMLSchema#string

P2860

Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence.

Hepatitis and solid organ transplantation.

Renal transplantation is not contraindicated in asymptomatic carriers of hepatitis B surface antigen.

Chronic viral hepatitis and the management of chronic renal failure.

Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience.

Twelve months of lamivudine treatment for chronic hepatitis B virus infection in renal transplant recipients.

Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival.

Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy.

P304

955-957

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1046/J.1440-1746.2001.02578.X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2001-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11755068

http://www.w3.org/2001/XMLSchema#string

P698

11595056

http://www.w3.org/2001/XMLSchema#string

P921

organ transplantation

Hepatitis B surface antigen-positive organ transplantation recipients: can lamivudine alter their fate?

about

P2860

P2860

Hepatitis B surface antigen-positive organ transplantation recipients: can lamivudine alter their fate?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P921